Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 435 entries
Sorted by: Best Match Show Resources per page
Expression of Factor IX cDNA Introduced into Human Marrow Stromal Cells by Electroporation.

Hematology (Amsterdam, Netherlands)

Fouillard L, Matthews KE, Guinn BA, Branch DR, Keating A.
PMID: 27414078
Hematology. 1998;3(5):347-54. doi: 10.1080/10245332.1998.11746408.

Management of hemophilia B with gene therapy is an attractive and potentially feasible goal since stringent regulation of the recombinant protein is not required and low circulating levels may be sufficient to prevent symptoms. We are investigating the potential...

Cite
Fouillard L, Matthews KE, Guinn BA, et al. Expression of Factor IX cDNA Introduced into Human Marrow Stromal Cells by Electroporation. Hematology. 1998;3(5):347-54doi: 10.1080/10245332.1998.11746408.
Fouillard, L., Matthews, K. E., Guinn, B. A., Branch, D. R., & Keating, A. (1998). Expression of Factor IX cDNA Introduced into Human Marrow Stromal Cells by Electroporation. Hematology (Amsterdam, Netherlands), 3(5), 347-54. https://doi.org/10.1080/10245332.1998.11746408
Fouillard, L, et al. "Expression of Factor IX cDNA Introduced into Human Marrow Stromal Cells by Electroporation." Hematology (Amsterdam, Netherlands) vol. 3,5 (1998): 347-54. doi: https://doi.org/10.1080/10245332.1998.11746408
Fouillard L, Matthews KE, Guinn BA, Branch DR, Keating A. Expression of Factor IX cDNA Introduced into Human Marrow Stromal Cells by Electroporation. Hematology. 1998;3(5):347-54. doi: 10.1080/10245332.1998.11746408. PMID: 27414078.
Copy Download .nbib Format: NLM
Trypanosoma cruzi Infection Induces Myocardial Nitric Oxide Synthase.

Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology

Huang Md H, Chan Md J, Wittner Md PhD M, Weiss Md Mph LM, Bacchi PhD J, Yarlett PhD N, Martinez Ba M, Morris Md PhD SA, Braunstein Bs VL, Factor Md SM, Tanowitz Md HB.
PMID: 25850327
Cardiovasc Pathol. 1997 May-Jun;6(3):161-6. doi: 10.1016/s1054-8807(96)00094-4.

Chagas' disease caused by Trypanosoma cruzi, is an important cause of myocarditis and cardiomyopathy. Acute and chronic infection is associated with myocardial dysfunction, including dysrhythmias, conduction disturbances, and congestive heart failure. Nitric oxide (NO) has been implicated in the...

Cite
Huang Md H, Chan Md J, Wittner Md PhD M, et al. Trypanosoma cruzi Infection Induces Myocardial Nitric Oxide Synthase. Cardiovasc Pathol. 1997;6(3):161-6doi: 10.1016/s1054-8807(96)00094-4.
Huang Md, H., Chan Md, J., Wittner Md PhD, M., Weiss Md Mph, L. M., Bacchi PhD, J., Yarlett PhD, N., Martinez Ba, M., Morris Md PhD, S. A., Braunstein Bs, V. L., Factor Md, S. M., & Tanowitz Md, H. B. (1997). Trypanosoma cruzi Infection Induces Myocardial Nitric Oxide Synthase. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology, 6(3), 161-6. https://doi.org/10.1016/s1054-8807(96)00094-4
Huang Md, H, et al. "Trypanosoma cruzi Infection Induces Myocardial Nitric Oxide Synthase." Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology vol. 6,3 (1997): 161-6. doi: https://doi.org/10.1016/s1054-8807(96)00094-4
Huang Md H, Chan Md J, Wittner Md PhD M, Weiss Md Mph LM, Bacchi PhD J, Yarlett PhD N, Martinez Ba M, Morris Md PhD SA, Braunstein Bs VL, Factor Md SM, Tanowitz Md HB. Trypanosoma cruzi Infection Induces Myocardial Nitric Oxide Synthase. Cardiovasc Pathol. 1997 May-Jun;6(3):161-6. doi: 10.1016/s1054-8807(96)00094-4. PMID: 25850327.
Copy Download .nbib Format: NLM
Symptomatic Acquired Haemophilia Due to Circulating Antibodies Against Both Factor VIII and IX in a Non-haemophiliac Patient.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion

Damodar S, Bhat P, Balasubramaniam S.
PMID: 25332547
Indian J Hematol Blood Transfus. 2014 Sep;30:90-2. doi: 10.1007/s12288-013-0270-3. Epub 2013 May 24.

Acquired haemophilia is a very rare condition, occurring in less than 2 per million populations. This condition is caused commonly by acquired antibodies against factor VIII and rarely by antibodies against factor IX. Here we describe an extremely rare...

Cite
Damodar S, Bhat P, Balasubramaniam S. Symptomatic Acquired Haemophilia Due to Circulating Antibodies Against Both Factor VIII and IX in a Non-haemophiliac Patient. Indian J Hematol Blood Transfus. 2013;30:90-2doi: 10.1007/s12288-013-0270-3.
Damodar, S., Bhat, P., & Balasubramaniam, S. (2014). Symptomatic Acquired Haemophilia Due to Circulating Antibodies Against Both Factor VIII and IX in a Non-haemophiliac Patient. Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 3090-2. https://doi.org/10.1007/s12288-013-0270-3
Damodar, Sharat, et al. "Symptomatic Acquired Haemophilia Due to Circulating Antibodies Against Both Factor VIII and IX in a Non-haemophiliac Patient." Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion vol. 30 (2014): 90-2. doi: https://doi.org/10.1007/s12288-013-0270-3
Damodar S, Bhat P, Balasubramaniam S. Symptomatic Acquired Haemophilia Due to Circulating Antibodies Against Both Factor VIII and IX in a Non-haemophiliac Patient. Indian J Hematol Blood Transfus. 2014 Sep;30:90-2. doi: 10.1007/s12288-013-0270-3. Epub 2013 May 24. PMID: 25332547; PMCID: PMC4192245.
Copy Download .nbib Format: NLM
Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey.

Haemophilia : the official journal of the World Federation of Hemophilia

Katz J.
PMID: 27213902
Haemophilia. 1996 Jan;2(1):28-31. doi: 10.1111/j.1365-2516.1996.tb00006.x.

This survey provides new information on the severity of factor IX deficiencies among patients being treated for haemophilia B and on the prevalence of factor IX inhibitors in this population. A questionnaire was sent to 150 haemophilia treatment centres...

Cite
Katz J. Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey. Haemophilia. 1996;2(1):28-31doi: 10.1111/j.1365-2516.1996.tb00006.x.
Katz, J. (1996). Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey. Haemophilia : the official journal of the World Federation of Hemophilia, 2(1), 28-31. https://doi.org/10.1111/j.1365-2516.1996.tb00006.x
Katz, J. "Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey." Haemophilia : the official journal of the World Federation of Hemophilia vol. 2,1 (1996): 28-31. doi: https://doi.org/10.1111/j.1365-2516.1996.tb00006.x
Katz J. Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey. Haemophilia. 1996 Jan;2(1):28-31. doi: 10.1111/j.1365-2516.1996.tb00006.x. PMID: 27213902.
Copy Download .nbib Format: NLM
Transient loss of vision as the presenting symptom of papillary fibroelastoma of aortic valve.

Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology

Shirani J, Bradlow JA, Metveyeva P, Losada M, Factor SM, Strom JA, Sisto D.
PMID: 25991541
Cardiovasc Pathol. 1997 Jul;6(4):237-40. doi: 10.1016/S1054-8807(96)00137-8.

Cardiac papillary fibroelastomas are benign endocardial papillomas. They may arise from atrial or ventricular endocardium but most commonly are located in cardiac valves. Their papillary structure, with loose, friable projections, results in a high tendency for embolism. Tumor fragments...

Cite
Shirani J, Bradlow JA, Metveyeva P, et al. Transient loss of vision as the presenting symptom of papillary fibroelastoma of aortic valve. Cardiovasc Pathol. 1997;6(4):237-40doi: 10.1016/S1054-8807(96)00137-8.
Shirani, J., Bradlow, J. A., Metveyeva, P., Losada, M., Factor, S. M., Strom, J. A., & Sisto, D. (1997). Transient loss of vision as the presenting symptom of papillary fibroelastoma of aortic valve. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology, 6(4), 237-40. https://doi.org/10.1016/S1054-8807(96)00137-8
Shirani, J, et al. "Transient loss of vision as the presenting symptom of papillary fibroelastoma of aortic valve." Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology vol. 6,4 (1997): 237-40. doi: https://doi.org/10.1016/S1054-8807(96)00137-8
Shirani J, Bradlow JA, Metveyeva P, Losada M, Factor SM, Strom JA, Sisto D. Transient loss of vision as the presenting symptom of papillary fibroelastoma of aortic valve. Cardiovasc Pathol. 1997 Jul;6(4):237-40. doi: 10.1016/S1054-8807(96)00137-8. PMID: 25991541.
Copy Download .nbib Format: NLM
Reconfigurable directional lasing modes in cavities with generalized PT symmetry.

Physical review letters

Lee JM, Factor S, Lin Z, Vitebskiy I, Ellis FM, Kottos T.
PMID: 25014817
Phys Rev Lett. 2014 Jun 27;112(25):253902. doi: 10.1103/PhysRevLett.112.253902. Epub 2014 Jun 25.

We introduce a new family of generalized PT-symmetric cavities that involve gyrotropic elements and support reconfigurable unidirectional lasing modes. We derive conditions for which these modes exist and investigate a simple electronic circuit that experimentally demonstrates their feasibility in...

Cite
Lee JM, Factor S, Lin Z, et al. Reconfigurable directional lasing modes in cavities with generalized PT symmetry. Phys Rev Lett. 2014;112(25):253902doi: 10.1103/PhysRevLett.112.253902.
Lee, J. M., Factor, S., Lin, Z., Vitebskiy, I., Ellis, F. M., & Kottos, T. (2014). Reconfigurable directional lasing modes in cavities with generalized PT symmetry. Physical review letters, 112(25), 253902. https://doi.org/10.1103/PhysRevLett.112.253902
Lee, J M, et al. "Reconfigurable directional lasing modes in cavities with generalized PT symmetry." Physical review letters vol. 112,25 (2014): 253902. doi: https://doi.org/10.1103/PhysRevLett.112.253902
Lee JM, Factor S, Lin Z, Vitebskiy I, Ellis FM, Kottos T. Reconfigurable directional lasing modes in cavities with generalized PT symmetry. Phys Rev Lett. 2014 Jun 27;112(25):253902. doi: 10.1103/PhysRevLett.112.253902. Epub 2014 Jun 25. PMID: 25014817.
Copy Download .nbib Format: NLM
Recurrent Cerebral Venous Thrombosis Associated with Elevated Factor VIII.

Journal of clinical neurology (Seoul, Korea)

Kim MJ, Cho AH, No YJ, Kim HY, Kim JS.
PMID: 20396536
J Clin Neurol. 2006 Dec;2(4):286-9. doi: 10.3988/jcn.2006.2.4.286. Epub 2006 Dec 20.

Cerebral venous thrombosis (CVT) rarely recurs, and the factors associated with a recurrence remain unclear. Recently, however, elevated plasma coagulation factor VIII has been considered a factor related to recurrent venous thromboembolism. Here we report a patient who had...

Cite
Kim MJ, Cho AH, No YJ, et al. Recurrent Cerebral Venous Thrombosis Associated with Elevated Factor VIII. J Clin Neurol. 2006;2(4):286-9doi: 10.3988/jcn.2006.2.4.286.
Kim, M. J., Cho, A. H., No, Y. J., Kim, H. Y., & Kim, J. S. (2006). Recurrent Cerebral Venous Thrombosis Associated with Elevated Factor VIII. Journal of clinical neurology (Seoul, Korea), 2(4), 286-9. https://doi.org/10.3988/jcn.2006.2.4.286
Kim, Mi Jung, et al. "Recurrent Cerebral Venous Thrombosis Associated with Elevated Factor VIII." Journal of clinical neurology (Seoul, Korea) vol. 2,4 (2006): 286-9. doi: https://doi.org/10.3988/jcn.2006.2.4.286
Kim MJ, Cho AH, No YJ, Kim HY, Kim JS. Recurrent Cerebral Venous Thrombosis Associated with Elevated Factor VIII. J Clin Neurol. 2006 Dec;2(4):286-9. doi: 10.3988/jcn.2006.2.4.286. Epub 2006 Dec 20. PMID: 20396536; PMCID: PMC2854983.
Copy Download .nbib Format: NLM
Future therapies for the prevention and treatment of venous and arterial thrombosis.

Expert opinion on investigational drugs

McKean ML, Adelman SJ.
PMID: 15991961
Expert Opin Investig Drugs. 1998 May;7(5):687-90. doi: 10.1517/13543784.7.5.687.

The incidence of thrombosis as a complication of invasive surgery, in cancer patients, as a cause or complication of stroke, acute myocardial infarction (AMI), thrombolysis, unstable angina (UA) or angioplasty is substantial. To better serve this patient population in...

Cite
McKean ML, Adelman SJ. Future therapies for the prevention and treatment of venous and arterial thrombosis. Expert Opin Investig Drugs. 1998;7(5):687-90doi: 10.1517/13543784.7.5.687.
McKean, M. L., & Adelman, S. J. (1998). Future therapies for the prevention and treatment of venous and arterial thrombosis. Expert opinion on investigational drugs, 7(5), 687-90. https://doi.org/10.1517/13543784.7.5.687
McKean, M L, and Adelman, S J. "Future therapies for the prevention and treatment of venous and arterial thrombosis." Expert opinion on investigational drugs vol. 7,5 (1998): 687-90. doi: https://doi.org/10.1517/13543784.7.5.687
McKean ML, Adelman SJ. Future therapies for the prevention and treatment of venous and arterial thrombosis. Expert Opin Investig Drugs. 1998 May;7(5):687-90. doi: 10.1517/13543784.7.5.687. PMID: 15991961.
Copy Download .nbib Format: NLM
Clinical trials of add-on medications in Parkinson's disease: Efficacy versus usefulness.

Parkinsonism & related disorders

Hauser RA, Zesiewicz TA, Factor SA, Guttman M, Weiner WJ.
PMID: 18591048
Parkinsonism Relat Disord. 1997 Jan;3(1):1-6. doi: 10.1016/s1353-8020(96)00042-9.

Clinical trials designed to evaluate the efficacy of new anti-parkinsonian agents often employ an 'add-on' protocol in which patients with motor fluctuations on levodopa are randomized to receive active medication or placebo. Levodopa doses may not be increased, but...

Cite
Hauser RA, Zesiewicz TA, Factor SA, et al. Clinical trials of add-on medications in Parkinson's disease: Efficacy versus usefulness. Parkinsonism Relat Disord. 1997;3(1):1-6doi: 10.1016/s1353-8020(96)00042-9.
Hauser, R. A., Zesiewicz, T. A., Factor, S. A., Guttman, M., & Weiner, W. J. (1997). Clinical trials of add-on medications in Parkinson's disease: Efficacy versus usefulness. Parkinsonism & related disorders, 3(1), 1-6. https://doi.org/10.1016/s1353-8020(96)00042-9
Hauser, R A, et al. "Clinical trials of add-on medications in Parkinson's disease: Efficacy versus usefulness." Parkinsonism & related disorders vol. 3,1 (1997): 1-6. doi: https://doi.org/10.1016/s1353-8020(96)00042-9
Hauser RA, Zesiewicz TA, Factor SA, Guttman M, Weiner WJ. Clinical trials of add-on medications in Parkinson's disease: Efficacy versus usefulness. Parkinsonism Relat Disord. 1997 Jan;3(1):1-6. doi: 10.1016/s1353-8020(96)00042-9. PMID: 18591048.
Copy Download .nbib Format: NLM
Constitutive expression of human coagulating factor IX in HeLa cells by homologous recombination of the promoter.

Science in China. Series C, Life sciences

Yang X, Wang F, Wang Y, Lu D, Qiu X, Xue J.
PMID: 18763084
Sci China C Life Sci. 2001 Feb;44(1):18-24. doi: 10.1007/BF02882068.

Constitutive expression of hFIX protein in nonhepatocytes was studied. The gene targeting vector was constructed and transferred into HeLa cells. With the detection system of PCR, we demonstrated that the endogenoushFIX promoter was replaced with anhCMV promoter when targeted...

Cite
Yang X, Wang F, Wang Y, et al. Constitutive expression of human coagulating factor IX in HeLa cells by homologous recombination of the promoter. Sci China C Life Sci. 2001;44(1):18-24doi: 10.1007/BF02882068.
Yang, X., Wang, F., Wang, Y., Lu, D., Qiu, X., & Xue, J. (2001). Constitutive expression of human coagulating factor IX in HeLa cells by homologous recombination of the promoter. Science in China. Series C, Life sciences, 44(1), 18-24. https://doi.org/10.1007/BF02882068
Yang, X, et al. "Constitutive expression of human coagulating factor IX in HeLa cells by homologous recombination of the promoter." Science in China. Series C, Life sciences vol. 44,1 (2001): 18-24. doi: https://doi.org/10.1007/BF02882068
Yang X, Wang F, Wang Y, Lu D, Qiu X, Xue J. Constitutive expression of human coagulating factor IX in HeLa cells by homologous recombination of the promoter. Sci China C Life Sci. 2001 Feb;44(1):18-24. doi: 10.1007/BF02882068. PMID: 18763084.
Copy Download .nbib Format: NLM
Optimal Immunofluorescent Staining for Human Factor IX and Infiltrating T Cells following Gene Therapy for Hemophilia B.

Journal of genetic syndromes & gene therapy

Rogers GL, Hoffman BE.
PMID: 23264888
J Genet Syndr Gene Ther. 2012 Aug 15; doi: 10.4172/2157-7412.s1-012.

Immunofluorescent imaging is a valuable tool for investigating the outcome of gene therapy within the transduced tissue. With a multi-labeling technique, it is possible to both characterize local expression of the transgene and to evaluate the severity of the...

Cite
Rogers GL, Hoffman BE. Optimal Immunofluorescent Staining for Human Factor IX and Infiltrating T Cells following Gene Therapy for Hemophilia B. J Genet Syndr Gene Ther. 2012;doi: 10.4172/2157-7412.s1-012.
Rogers, G. L., & Hoffman, B. E. (2012). Optimal Immunofluorescent Staining for Human Factor IX and Infiltrating T Cells following Gene Therapy for Hemophilia B. Journal of genetic syndromes & gene therapy, . https://doi.org/10.4172/2157-7412.s1-012
Rogers, Geoffrey L, and Hoffman, Brad E. "Optimal Immunofluorescent Staining for Human Factor IX and Infiltrating T Cells following Gene Therapy for Hemophilia B." Journal of genetic syndromes & gene therapy vol. (2012). doi: https://doi.org/10.4172/2157-7412.s1-012
Rogers GL, Hoffman BE. Optimal Immunofluorescent Staining for Human Factor IX and Infiltrating T Cells following Gene Therapy for Hemophilia B. J Genet Syndr Gene Ther. 2012 Aug 15; doi: 10.4172/2157-7412.s1-012. PMID: 23264888; PMCID: PMC3526188.
Copy Download .nbib Format: NLM
Factorial structure of cognitive activity using a neuropsychological test battery.

Behavioural neurology

Ardila A, Rosselli M, Bateman JR.
PMID: 24487288
Behav Neurol. 1994;7(2):49-58. doi: 10.3233/BEN-1994-7202.

A general neuropsychological test battery was assembled and individually given to a 98-subject sample, aged 11-12 years old. The battery included some basic and common tests routinely used in the evaluation of language, memory, spatial abilities, concept formation, and...

Cite
Ardila A, Rosselli M, Bateman JR. Factorial structure of cognitive activity using a neuropsychological test battery. Behav Neurol. 1994;7(2):49-58doi: 10.3233/BEN-1994-7202.
Ardila, A., Rosselli, M., & Bateman, J. R. (1994). Factorial structure of cognitive activity using a neuropsychological test battery. Behavioural neurology, 7(2), 49-58. https://doi.org/10.3233/BEN-1994-7202
Ardila, A, et al. "Factorial structure of cognitive activity using a neuropsychological test battery." Behavioural neurology vol. 7,2 (1994): 49-58. doi: https://doi.org/10.3233/BEN-1994-7202
Ardila A, Rosselli M, Bateman JR. Factorial structure of cognitive activity using a neuropsychological test battery. Behav Neurol. 1994;7(2):49-58. doi: 10.3233/BEN-1994-7202. PMID: 24487288.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 435 entries